TechFlow news, October 23: Hyperliquid Strategies Inc. filed an S-1 registration statement with the U.S. Securities and Exchange Commission, intending to issue up to 160 million shares of common stock under a committed equity financing agreement (Facility) with Chardan Capital Markets, raising up to $1 billion upon completion of a dual merger transaction with Sonnet BioTherapeutics Holdings and Rorschach I LLC. The proceeds will be used for general corporate purposes, including potential purchases of HYPE Token.
Add to Favorites
Share to Social Media
